Primary Objectives~- To estimate progression free survival (PFS) after locally ablative therapy and erlotinib in EGFR-mutant NSCLC patients who progressed on prior EGFR-TKI therapy~Secondary Objectives~To evaluate local control of sites previously progressive on erlotinib following stereotactic radiosurgery (SRS) followed by erlotinib~To estimate overall survival (OS) after locally ablative therapy and erlotinib in EGFR-mutant NSCLC patients who progressed on prior EGFR-TKI therapy~To characterize the toxicity of SRS~To characterize the toxicity of erlotinib when preceded by SRS~Exploratory Objectives~To explore if VeriStrat results at initial progression are associated with longer PFS or OS after study treatment~To explore if VeriStrat results following completion of SRS are associated with longer PFS or OS after re-initiation of erlotinib~To explore whether poor VeriStrat signatures ever turn to good signatures with the study therapy, and to explore PFS and OS of patients whose signature changes
- Progression free survival after locally ablative therapy and erlotinib in EGFR patients progressed after EGFR-TKI therapy